New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2013
10:01 EDTURI, NKE, CORR, SBGL, M, SXCP, ITC, NEOG, SEAC, THRX, NMM, MANU, LGCY, IDIX, CONE, CBBOn the Fly: Analyst Initiation Summary
Today’s noteworthy initiations include: Cincinnati Bell (CBB) initiated with a Hold at Deutsche Bank... CyrusOne (CONE) initiated with a Buy at Deutsche Bank... CyrusOne (CONE) initiated with a Neutral at BofA/Merrill... Idenix (IDIX) initiated with a Neutral at RW Baird... Legacy Reserves (LGCY) initiated with an Overweight at Barclays... Manchester United (MANU) initiated with an Outperform at Raymond James... Navios Maritime Partners (NMM) initiated with a Buy at Citigroup... Theravance (THRX) initiated with an Outperform at RW Baird... Neogen (NEOG) initiated with a Neutral at Sidoti... SeaChange (SEAC) initiated with a Buy at Dougherty... ITC Holdings (ITC) initiated with a Neutral at ISI Group... Kohl's (KSS) initiated with a Hold at Maxim... SunCoke Energy (SXCP) initiated with a Buy at BofA/Merrill... Macy's (M) initiated with a Buy at Maxim... Sibanye Gold (SBGL) initiated with a Neutral at JPMorgan... SunCoke Energy (SXCP) initiated with a Neutral at JPMorgan... SunCoke Energy (SXCP) initiated with an Outperform at Credit Suisse... Nike (NKE) initiated with a Neutral at Wedbush... CorEnergy (CORR) initiated with a Hold at KeyBanc... United Rentals (URI) initiated with a Buy at BofA/Merrill.
News For CBB;CONE;IDIX;LGCY;MANU;NMM;THRX;SEAC;NEOG;ITC;SXCP;M;SBGL;CORR;NKE;URI From The Last 14 Days
Check below for free stories on CBB;CONE;IDIX;LGCY;MANU;NMM;THRX;SEAC;NEOG;ITC;SXCP;M;SBGL;CORR;NKE;URI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 11, 2014
09:19 EDTMMacy's management to meet with JPMorgan
Meetings to be held in Boston on April 15-16 hosted by JPMorgan.
April 10, 2014
16:13 EDTTHRXTheravance announces Phase 2b study initiated with TD-4208 in COPD
Subscribe for More Information
10:28 EDTITCITC Holdings to host investor day
Subscribe for More Information
10:00 EDTNKEOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:24 EDTLGCYLegacy Reserves announces series A preferred unit offering, no amount given
Subscribe for More Information
08:10 EDTNKENike upgraded at Macquarie
As previously reported, Macquarie upgraded Nike to Outperform from Neutral. The firm is positive on Nike based on expectations for overseas revenue acceleration, strong futures orders, valuation, lower cost of production in Vietnam and sportswear category growth. Price target raised to $84 from $80.
05:57 EDTNKENike upgraded to Outperform from Neutral at Macquarie
April 9, 2014
09:20 EDTMBofA/Merrill's retail analysts hold an analyst/industry conference call
Subscribe for More Information
07:23 EDTIDIXEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
April 8, 2014
12:12 EDTNKEOn The Fly: Midday Wrap
Subscribe for More Information
11:47 EDTIDIXIdenix price target raised to $9 from $6 at Leerink
Leerink raised Idenix's price target to $9 from $6 citing positive IDX21437 data.
10:03 EDTNKEOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:09 EDTNKEOn The Fly: Pre-market Movers
HIGHER: BioScrip (BIOS), up 6.7% after stock was named as a stock pick and a potential takeover target by Oscar Schafer while speaking on CNBC... Nokia (NOK), up 5% after deal to sell substantially all of its Devices & Services business to Microsoft (MSFT) receives regulatory approval in China... Ctrip.com (CTRP), up 4.6% after Bloomberg said, citing sources, that the company is in talks with Baidu-controlled (BIDU) Qunar (QUNR) about a partnership or a potential merger... Plug Power (PLUG), up 4.6% after CEO discusses plan to expand fuel cells to trucks in interview... FireEye (FEYE), up 2.5% following upgrade at Wedbush... Twitter (TWTR), up 2% following initiation of coverage with a Buy rating at at Janney Capital... Nike (NKE), up 1.75% after upgraded at Stifel. LOWER: Gigamon (GIMO), down 23% after lowering revenue outlook, shares downgraded at Pacific Crest... LivePerson (LPSN), down 3% after announcing resignation of EVP, Worldside Sales, shares downgraded at Benchmark... Cisco (CSCO), down 0.5% following downgrade to Hold from Buy at Wunderlich.
07:05 EDTNKENike upgraded at Stifel
Subscribe for More Information
06:23 EDTNKENike upgraded to Buy from Hold at Stifel
Subscribe for More Information
April 7, 2014
16:28 EDTIDIXOn The Fly: Closing Wrap
Subscribe for More Information
13:31 EDTIDIXIdenix risk/reward remains favorable, says UBS
UBS said Idenix's IDX21437 update this morning supports its favorable risk/reward thesis. Shares are Buy rated with an $11 price target.
08:56 EDTSEACSeaChange lack of warning could be seen as positive, says BWS Financial
BWS Financial believes SeaChange shares should begin to move higher after the company's in-line Q4 report came with no additional warnings and management reasserted that revenue that was delayed in FY14 would be recognized in FY15. BWS maintains a Strong Buy rating and $30 price target on SeaChange.
07:15 EDTIDIXIdenix announces promising clinical data, continued progress in HCV programs
Idenix Pharmaceuticals announced continued progress of the Company's program to develop nucleotide prodrug inhibitors for the treatment of hepatitis C virus, or HCV, infection. Idenix is reporting potent antiviral activity of mean maximum 4.2-4.3 log10 IU/mL reductions for patients infected with HCV genotype 1, 2 or 3 receiving 300 mg once daily of IDX21437 in the seven-day proof-of-concept portion of a phase I/II clinical trial. Based on this progress, the Company's goal is to initiate a combination clinical trial of IDX21437 and samatasvir, a pan-genotypic NS5A inhibitor, in mid-2014. In addition, Idenix has selected a follow-on uridine-based nucleotide prodrug, IDX21459, from its ongoing nucleotide discovery program and initiated enrollment for the healthy volunteer portion of a phase I clinical trial. In January, Idenix initiated the seven-day proof-of-concept portion of a phase I/II clinical trial for IDX21437. The trial completed enrollment of 44 treatment-naïve, genotype, or GT, 1, 2 or 3 HCV-infected patients. Patients were randomized to receive once-daily doses of placebo, 50 mg, 150 mg, or 300 mg of IDX21437 for seven days. In April 2014, Idenix initiated enrollment for the healthy volunteer portion of a phase I clinical trial of IDX21459 in Europe. This portion of the study is expected to enroll approximately 50 healthy volunteers and will evaluate once-daily doses of IDX21459 ranging from 10 mg – 300 mg. The proof-of-concept portion of the study is expected to enroll a total of 40 treatment-naïve, genotype 1 HCV-infected patients who will receive once-daily doses of placebo, 50 - 300 mg of IDX21459 for seven days. IDX21459 has shown a favorable preclinical profile including potent, pan-genotypic activity and favorable safety with respect to cardiac, mitochondrial and genotoxicity assessments.
07:04 EDTCBBCincinnati Bell to sell wireless spectrum licenses to Verizon Wireless
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use